Specifically, deficiency or splicing abnormalities in RASSF4 expression, as frequently observed in STAD, can reshape the immune landscape by altering immune cell infiltration and modulating key immune signaling pathways. This evidence concerns the gene RASSF4 and gastric adenocarcinoma.